Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

An otherwise healthy 7171-year-old female is evaluated in the emergency department for severe unilateral head pain that began 33 days ago. She notes exquisite tenderness when brushing her hair and describes an aching fatigue in her jaw muscles during meals. Blood tests demonstrate an erythrocyte sedimentation rate (ESR) of 98 mm/h98 \text{ mm/h} and a C-reactive protein (CRP) of 45 mg/L45 \text{ mg/L}. Order the following therapeutic and surveillance interventions in the correct chronological sequence for the longitudinal management of this condition.

  1. 1Administer high-dose systemic glucocorticoids to prevent irreversible ischemic complications.
  2. 2Obtain a temporal artery biopsy to establish a definitive tissue diagnosis.
  3. 3Monitor serial clinical symptoms and acute-phase reactants to guide a gradual medication taper.
  4. 4Initiate a steroid-sparing immunomodulator (e.g., tocilizumab) if disease relapse occurs during dose reduction.
  5. 5Perform annual imaging surveillance to evaluate for the development of aortic aneurysms.

Answer

The correct sequence begins with immediate glucocorticoid administration to prevent irreversible vision loss. Second, a temporal artery biopsy is obtained to confirm the diagnosis (which remains accurate even after days of steroid use). Third, the patient is monitored clinically and with serial inflammatory markers to guide a gradual steroid taper. Fourth, if disease relapse occurs during the taper, a steroid-sparing agent like tocilizumab is initiated. Finally, long-term monitoring must include imaging to evaluate for late-onset aortic aneurysms.
The standard of care for suspected giant cell arteritis dictates that empiric high-dose glucocorticoids must be initiated instantly to prevent blindness. A temporal artery biopsy is then scheduled within 1-2 weeks. After stabilization, the treatment evaluation phase relies on serial ESR/CRP and symptom checks to carefully taper the steroids over many months. If relapses occur, targeted biologic therapy is introduced. Lastly, because of the disease's pathophysiology, long-term structural monitoring for aortic aneurysms is required indefinitely.

Step-by-Step Solution

1
Administer high-dose systemic glucocorticoids.
Prevents anterior ischemic optic neuropathy and irreversible blindness.
In highly suspected giant cell arteritis, empiric treatment is a medical emergency and must precede definitive diagnostic testing to preserve vision.
2
Obtain a temporal artery biopsy.
Provides definitive histological confirmation of arteritis.
Long-term steroid therapy carries heavy morbidity. A tissue diagnosis is required to justify long-term exposure, and the biopsy remains diagnostic up to 2 weeks after starting steroids.
3
Monitor serial clinical symptoms and acute-phase reactants.
Guides the progressive tapering of glucocorticoids.
Steroids must be slowly tapered over months to avoid relapses while minimizing the risk of osteoporosis, diabetes, and infections. Monitoring ESR and CRP helps ensure the disease remains suppressed.
4
Initiate a steroid-sparing immunomodulator.
Achieves disease control while allowing for further steroid reduction.
If the patient fails the steroid taper (relapse of headache, jaw claudication, or rising ESR/CRP), an agent like tocilizumab is indicated to achieve remission.
5
Perform annual imaging surveillance of the aorta.
Detects asymptomatic large-vessel complications.
Giant cell arteritis involves the aorta and its major branches in up to 30% of patients, presenting a lifelong risk for aortic aneurysm and dissection that requires structured monitoring.

Key Concept

Chronological treatment sequencing, tapering, and surveillance in Giant Cell Arteritis
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic